Publications
74
Citations
384
Est. group size
—
Recurring co-author estimate
Active years
16
Publishing since 2011
Ha Tran's work centers on cancer biology and treatment, with a particular focus on colorectal cancer and targeted therapies such as antibody-drug conjugates (engineered antibodies that deliver toxic drugs directly to cancer cells) that target EGFR-related proteins like epiregulin. Related work explores how tumor cells adapt to survive drug treatments (such as MAPK-pathway inhibitors) and touches on broader topics in clinical medicine, including gene therapy trial design and AI tools in clinical practice. Prospective students would be working at the intersection of cancer pharmacology, molecular biology, and translational/clinical research.
Publication output has grown substantially in recent years, rising from a handful of papers per year in the late 2010s to a sharp increase in 2025-2026, partly reflecting multiple supplementary figure/table entries tied to a single major study.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Figure S8 from Antibody–Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer
2026
- Figure S3 from Antibody–Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer
2026
- Figure S10 from Antibody–Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer
2026
- Figure S4 from Antibody–Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer
2026
- Figure S1 from Antibody–Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer
2026
- Figure S9 from Antibody–Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer
2026
- Figure S5 from Antibody–Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer
2026
- Figure S2 from Antibody–Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer
2026
- Figure S7 from Antibody–Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer
2026
- Figure S6 from Antibody–Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer
2026
- Noteworthy – Integration of Ambient AI Scribe Technology in Internal Medicine Residency Clinic
Journal of General Internal Medicine · 2025
- Study Designs and Crafting Endpoints for Gene Therapy Development Programs in Rare Disease: A Narrative Review
Advances in Therapy · 2025
- Adaptive Plasticity Tumor Cells Modulate MAPK-Targeting Therapy Response in Colorectal Cancer
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Figure S5 from Antibody–Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer
2025
- Figure S9 from Antibody–Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer
2025
- The Permanente Journal×13
- Journal of General Internal Medicine×3
- bioRxiv (Cold Spring Harbor Laboratory)×3
- Circulation×3
- Cancer Research×2
- Bert H. O’Neil
Medicine · Indiana University
- Mingjia Li
Medicine · The Ohio State University
- Xiaoyan Wang
Medicine · Indiana University
- Yusuf Açıkgöz
Medicine · The Ohio State University
- Eric D. Miller
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile